Schwab Charles Investment Management Inc. increased its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 2.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 472,516 shares of the biopharmaceutical company’s stock after acquiring an additional 11,647 shares during the quarter. Schwab Charles Investment Management Inc. owned about 1.05% of Vanda Pharmaceuticals worth $8,459,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Legal & General Group Plc increased its holdings in Vanda Pharmaceuticals by 37.4% in the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 3,022 shares in the last quarter. Kopp Investment Advisors LLC purchased a new stake in Vanda Pharmaceuticals in the 2nd quarter worth approximately $196,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Vanda Pharmaceuticals in the 3rd quarter worth approximately $277,000. Voya Investment Management LLC grew its holdings in Vanda Pharmaceuticals by 29.7% during the 2nd quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock valued at $328,000 after buying an additional 4,605 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd grew its holdings in Vanda Pharmaceuticals by 46.3% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 20,510 shares of the biopharmaceutical company’s stock valued at $335,000 after buying an additional 6,487 shares in the last quarter. 88.43% of the stock is owned by institutional investors.

Shares of Vanda Pharmaceuticals Inc. (NASDAQ VNDA) opened at $15.20 on Tuesday. The stock has a market cap of $689.64, a P/E ratio of -47.50 and a beta of 1.28. Vanda Pharmaceuticals Inc. has a fifty-two week low of $11.90 and a fifty-two week high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). The firm had revenue of $41.30 million during the quarter, compared to the consensus estimate of $43.90 million. Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.01) EPS. analysts predict that Vanda Pharmaceuticals Inc. will post -0.44 EPS for the current year.

A number of brokerages have issued reports on VNDA. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 19th. Oppenheimer set a $26.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, October 29th. BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Piper Jaffray Companies increased their price objective on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Thursday, September 14th. Finally, ValuEngine lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $21.50.

WARNING: “Schwab Charles Investment Management Inc. Grows Stake in Vanda Pharmaceuticals Inc. (VNDA)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2018/01/02/schwab-charles-investment-management-inc-grows-stake-in-vanda-pharmaceuticals-inc-vnda.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Stock Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related stocks with our FREE daily email newsletter.